SETDB1 Antibodies

Structure of SETDB1

SETDB1 is a histone methyltransferase with a molecular weight of approximately 150 kDa. Its specific molecular weight may fluctuate slightly due to post-translational modifications or different transcriptional splicing variants.

This protein is composed of approximately 1,300 amino acids, and its core functional domain is the highly conserved SET domain at the C-terminal, which is responsible for catalyzing the trimethylation of lysine at position 9 of histone H3. The tertiary structure of proteins forms a specific binding pocket that can recognize and bind S-adenosylmethionine as a methyl donor, and precisely target specific regions of chromatin through its adjacent Tudor and MBD-like domains, thereby regulating gene expression.

Fig. 1 Protein domain structure of SETDB1.¹

Key structural properties of SETDB1:

• Contains the highly conserved SET domain
• With Tudor structure domain and structure domain MBD samples
• The tertiary structure to form a combined with pockets

Functions of SETDB1

The main function of the SETDB1 protein is to act as a histone methyltransferase to catalyze gene silencing. However, it is also widely involved in a variety of key biological processes, including the maintenance of genomic stability, the determination of cell fate, and the occurrence and development of diseases.

Unlike histone methyltransferases with broad substrate specificity, SETDB1 exhibits high specificity for the H3K9 site. This specificity makes it an exact "switch" in the epigenetic regulatory network, and its abnormal activity is closely related to a variety of developmental diseases and cancers.

Applications of SETDB1 and SETDB1 Antibody in Literature

• Fukuda, Kei, and Yoichi Shinkai. "SETDB1-mediated silencing of retroelements." Viruses 12.6 (2020): 596. https://doi.org/10.3390/v12060596 

The article indicates that SETDB1 is a histone methyltransferase that maintains genomic stability by silencing retrotransposions through catalyzing H3K9me3. It is highly expressed in various tumors and works in synergy with KAP1, HUSH complex, etc. to inhibit endogenous retroviruses. The methylation mediated by it can continue during replication.

• She X, Wu Q, et al. "SETDB1 methylates MCT1 promoting tumor progression by enhancing the lactate shuttle." Advanced Science 10.28 (2023): 2301871. https://doi.org/10.1002/advs.202301871 

The article indicates that SETDB1 stabilizes MCT1 by methylating the K473 site of the MCT1 protein and blocking its autophagic degradation. This modification promotes glycolysis, lactate shuttle and M2 polarization of tumor-associated macrophages in colorectal cancer, which is associated with a poor prognosis for patients.

• Luo, Fei, et al. "LINC00115 promotes chemoresistant breast cancer stem-like cell stemness and metastasis through SETDB1/PLK3/HIF1α signaling." Molecular Cancer 23.1 (2024): 60. https://doi.org/10.1186/s12943-024-01975-3 

Research has found that LINC00115 can act as a scaffold to link SETDB1 and PLK3, promoting the methylation of PLK3 and thereby stabilizing HIF1α. This feedback loop enhances the characteristics of breast cancer stem cells, leading to chemotherapy resistance and metastasis. Targeting this pathway is expected to become a new therapeutic strategy.

• K., Wang, T., et al. "Hepatocellular SETDB1 regulates hepatic ischemia-reperfusion injury through targeting lysine methylation of ASK1 signal." Research 6 (2023): 0256. https://doi.org/10.34133/research.0256 

Research has found that SETDB1, in hepatic ischemia-reperfusion injury, activates the downstream JNK/p38 pathway by methylating ASK1, thereby exacerbating inflammation and apoptosis. Inhibiting SETDB1 can significantly alleviate liver injury, suggesting it as a potential therapeutic target.

• Johnson, Eleanor, Kiarash Salari, and Shujie Yang. "SETDB1: A perspective into immune cell function and cancer immunotherapy." Immunology 169.1 (2023): 3-12. https://doi.org/10.1111/imm.13619

Research has found that SETDB1, as a histone methyltransferase, is involved in the normal development and functional regulation of B cells and T cells. In tumor cells, its overexpression can help tumor immune escape by silencing reverse transcription elements, inhibiting interferon pathways, and other means, thereby affecting the efficacy of immunotherapy.

Creative Biolabs: SETDB1 Antibodies for Research

Creative Biolabs specializes in the production of high-quality SETDB1 antibodies for research and industrial applications. Our portfolio includes monoclonal antibodies tailored for ELISA, Flow Cytometry, Western blot, immunohistochemistry, and other diagnostic methodologies.

• Custom SETDB1 Antibody Development: Tailor-made solutions to meet specific research requirements.
• Bulk Production: Large-scale antibody manufacturing for industry partners.
• Technical Support: Expert consultation for protocol optimization and troubleshooting.
• Aliquoting Services: Conveniently sized aliquots for long-term storage and consistent experimental outcomes.

For more details on our SETDB1 antibodies, custom preparations, or technical support, contact us at email.